British aneurysm nimodipine after subarachnoid hemorrhage

Completed

Phase N/A Results

Trial Description

To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes following subarachnoid hemorrhage.

Interventions

  • Nimodipine (NimotopĀ®)Drug
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Double-blind, placebo-controlled, randomized trial of 554 patients at 4 regional neurosurgical units in the United Kingdom.

Patient Involvement

Patients were randomized to receive placebo or nimodipine 60 mg given orally every four hours for 21 days. All patients were followed for up to three months.

Outcomes

Type Measure Time Frame Safety Issue
Primary Incidence of cerebral infarction at 3 months.
Secondary Incidence of poor outcome (dead, vegetative state, and severe disability).

Sponsors

Bayer UK